Wall Street analyst estimates for BioNTech SE (BNTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 20 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 24 |
| Avg rating (1-5) | 0.83 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.85 | ||
| 2026-08-04 | $-3.70 | $-2.40 | -54.3% |
| 2026-05-05 | $-2.43 | $-2.54 | +4.4% |
| 2026-03-10 | $-1.44 | $-0.22 | -556.7% |
| 2025-11-03 | $-0.14 | $-1.12 | +87.5% |
| 2025-08-04 | $-1.82 | $-2.69 | +32.3% |
| 2025-05-05 | $-1.82 | $-2.48 | +26.5% |
| 2025-03-10 | $1.15 | $0.46 | +148.7% |
Valuation Ratios
| Price / Book | 1.18 |
| EV / EBITDA | -14.41 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.6M | $127.6M | $108.6M | $482.3M | $18.98B | $17.31B | $3.82B | $2.75B | $2.76B |
| Cost of Revenue | $9.3M | $13.7M | $17.4M | $59.3M | $2.91B | $3.00B | $599.8M | $541.3M | $616.5M |
| Gross Profit | $52.3M | $113.9M | $91.2M | $423.0M | $16.07B | $14.32B | $3.22B | $2.21B | $2.14B |
| Research & Development | $85.5M | $143.1M | $226.5M | $645.0M | $949.2M | $1.54B | $1.78B | $2.25B | $2.02B |
| Selling, General & Admin | $29.5M | $27.1M | $43.3M | $108.5M | $327.2M | $541.2M | $557.7M | $599.0M | $698.2M |
| Operating Expenses | $113.6M | $167.7M | $272.7M | $505.4M | $781.4M | $1.67B | $2.53B | $3.52B | $2.76B |
| Operating Income | -$61.3M | -$53.9M | -$181.5M | -$82.4M | $15.28B | $12.64B | $690.4M | -$1.31B | -$623.9M |
| EBITDA | -$74.7M | -$24.0M | -$143.8M | -$105.1M | $15.00B | $13.10B | $1.38B | -$367.1M | -$628.0M |
| Interest Expense | $651443 | $1.8M | $1.7M | $1.9M | $5.6M | $15.8M | $7.8M | $13.2M | $13.6M |
| Pre-tax Income | -$85.9M | -$47.7M | -$179.4M | -$145.8M | $15.05B | $12.95B | $1.19B | -$677.7M | -$1.01B |
| Income Tax | $45000 | $600000 | -$200000 | -$161.0M | $4.75B | $3.52B | $255.8M | -$12.4M | $81.9M |
| Net Income | -$85.7M | -$48.0M | -$179.1M | $15.2M | $10.29B | $9.43B | $930.3M | -$665.3M | -$1.09B |
| EPS | $-0.38 | $-0.21 | $-0.85 | $0.06 | $43.87 | $38.08 | $3.87 | $-2.77 | $-4.51 |
| EPS (Diluted) | $-0.38 | $-0.21 | $-0.85 | $0.06 | $41.21 | $37.09 | $3.83 | $-2.77 | $-4.51 |
| Shares Outstanding (Diluted) | $226.9M | $226.9M | $211.5M | $248.5M | $259.7M | $249.8M | $242.7M | $240.4M | $241.7M |
Price
| Price | $96.06 |
| Market Cap | $24.1B |
| Exchange | NASDAQ |
| Country | DE |
Related companies: BIIB · DXCM · GMAB · INCY · NTRA · PHG · RPRX
Explore sector: Healthcare · Biotechnology
More sections of BNTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks